Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bevonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 13/20 | 0.45 |
| ▸ | CHRM1 known ✓ | P11229 | 7/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Poldine SCHEMBL250977 | 0.97 | CHRM2 (0.48) | CHRM2CHRM3CHRM1CYP2D6CHRM4 | |
| Bevonium SCHEMBL28439272 | 0.95 | CHRM2 (0.46) | CHRM2CHRM3CHRM1CYP2D6CHRM4 | |
| Bevonium SCHEMBL1650540 | 0.92 | CHRM2 (0.51) | CHRM2CHRM3CHRM1CYP2D6CHRM4 | |
| Poldine SCHEMBL1641786 | 0.89 | CHRM2 (0.55) | CHRM2CHRM3CHRM1CYP2D6CHRM4 | |
| Bevonium SCHEMBL28086190 | 0.87 | CHRM2 (0.47) | CHRM2CHRM3CHRM1CYP2D6CHRM4 | |
| Oxypyrronium SCHEMBL29388831 | 0.77 | POLB (0.57) | CHRM2CHRM3CHRM1CYP2D6CHRM4 | |
| Oxypyrronium SCHEMBL916858 | 0.76 | CHRM2 (0.56) | CHRM2CHRM3CHRM1CYP2D6CHRM4 | |
| Poldine SCHEMBL28086707 | 0.75 | CHRM2 (0.67) | CHRM2CHRM3CHRM1CYP2D6CHRM4 | |
| SCHEMBL1087915 | 0.72 | CHRM2 (0.47) | CHRM2CHRM3CHRM1CYP2D6CHRM4 | |
| SCHEMBL1087914 | 0.72 | CHRM2 (0.47) | CHRM2CHRM3CHRM1CYP2D6CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306412-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2009-12-10 | — | — | US | claimed |
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-2041108-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | Antibe Therapeutics Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2008009118-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | claimed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| US-7186753-B1 | Pharmaceutical compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | claimed |
| JP-2002541233-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1252133-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-10-30 | — | — | EP | claimed |
| EP-1192129-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-04-03 | — | — | EP | claimed |
| EP-1169294-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306412-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | HRH4, HRH2, HNMT | CHRM3 407/4885CHRM1 1563/4885CHRM2 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.